ASTRAZENECA PHARMA INDIA LTD. - Intimation Under Regulation 30 Of SEBI (Listing Obligations And Disclosure Requirements) Regulation, 2015
23 Sep 2024
This is to inform that the Company has received permission for sale and distribution of Durvalumab 120mg/2.4 ml and 500mg/10 ml solution for infusion (Imfinzi) from the Central Drugs Standard Organisation for additional indication. The details of the same is mentioned in the attached letter.
Source:
BSE India